Patient characteristics at the time of study entry
| Patient no. . | Sex . | Age, y . | Laboratory findings . | Clinical signs and symptoms . | Duration . | Treatment . | |||
|---|---|---|---|---|---|---|---|---|---|
| VCA . | EBNA . | EBV-DNA . | EA . | ||||||
| 1 | M | 27 | >640 | Negative | N/A | mRNA + | Continuous fever, severe fatigue, abdominal lymphadenopathy, splenomegaly | 12 y | Aspirin, IV IgG, steroids, acyclovir |
| 2 | F | 42 | >640 | Negative | <4 | ND | Fever, sleep disturbance, headaches, flulike malaise, myalgia, sore throat, paresthesias, reduced daily activity | 6 y | Acyclovir, IV IgG |
| 3 | M | 18 | >640 | Negative | 97 | ND | Severe fatigue, sleep disturbance, night sweats, intermittent lymphadenopathy | 4 y | Steroid |
| 4 | F | 45 | >640 | Negative | <4 | ND | Fatigue, headaches, arthralgia, night sweats, intermittent lymphadenopathy | 4 y | Acyclovir |
| 5 | F | 18 | >1280 | Negative | <4 | ND | Fatigue, malaise, oral and genitourinary ulcer, cognitive impairment, sleep disturbance | 1 y | Acyclovir |
| 6 | F | 2 | N/A | Negative | 400 | mRNA + | Persistent fever | 8 mo | Gancyclovir |
| 7 | F | 2 | N/A | Negative | >4000 | ND | Persistent fever, hepato- and splenomegaly | 6 mo | Acyclovir, gancyclovir, foscavir |
| 8 | F | 37 | N/A | Positive | N/A | >1:150 | Fatigue, cervical lymphadenopathy, headache, sore throat, night sweats | 6 mo | Acyclovir |
| Patient no. . | Sex . | Age, y . | Laboratory findings . | Clinical signs and symptoms . | Duration . | Treatment . | |||
|---|---|---|---|---|---|---|---|---|---|
| VCA . | EBNA . | EBV-DNA . | EA . | ||||||
| 1 | M | 27 | >640 | Negative | N/A | mRNA + | Continuous fever, severe fatigue, abdominal lymphadenopathy, splenomegaly | 12 y | Aspirin, IV IgG, steroids, acyclovir |
| 2 | F | 42 | >640 | Negative | <4 | ND | Fever, sleep disturbance, headaches, flulike malaise, myalgia, sore throat, paresthesias, reduced daily activity | 6 y | Acyclovir, IV IgG |
| 3 | M | 18 | >640 | Negative | 97 | ND | Severe fatigue, sleep disturbance, night sweats, intermittent lymphadenopathy | 4 y | Steroid |
| 4 | F | 45 | >640 | Negative | <4 | ND | Fatigue, headaches, arthralgia, night sweats, intermittent lymphadenopathy | 4 y | Acyclovir |
| 5 | F | 18 | >1280 | Negative | <4 | ND | Fatigue, malaise, oral and genitourinary ulcer, cognitive impairment, sleep disturbance | 1 y | Acyclovir |
| 6 | F | 2 | N/A | Negative | 400 | mRNA + | Persistent fever | 8 mo | Gancyclovir |
| 7 | F | 2 | N/A | Negative | >4000 | ND | Persistent fever, hepato- and splenomegaly | 6 mo | Acyclovir, gancyclovir, foscavir |
| 8 | F | 37 | N/A | Positive | N/A | >1:150 | Fatigue, cervical lymphadenopathy, headache, sore throat, night sweats | 6 mo | Acyclovir |
F indicates female; M, male; N/A, not available; ND, not done; VCA, anti–viral capsid antigen IgG (values detected in normal EBV-seropositive donors range from 1:60 to 1:320); EBNA, anti-EBV nuclear antigen IgG (values detected in normal EBV-seropositive donors range from 1:20 to 1:160); EBV-DNA, number of copies/μg of DNA in peripheral blood (the sensitivity of the real-time polymerase chain reaction is 4 copies/μg; values detected in normal EBV-seropositive donors range from 0 to 200 copies/μg of DNA); EA, early antigen; and IV IgG, intravenous immunoglobulin.